Table 1. The Characteristics of the Included Studies

Study ID	Participants	Inclusion/Exclusion criteria	Intervention	Treatment period
Vanzifehkah S16) (2016)	N = 26, male/female : 15/11, Age range : 23-68 (mean 41.00)	1) Inclusion criteriai) Patients with presence of chronic rhinosinusitis symptoms for at least 12 weeksii) Positive CT result indicating the opacity and swelling of the sinusiii) Patients 18 to 75 years of both gendersiv) No treatment with systemic or nasal antibiotics or corticosteroids within 4 weeks before visitv) No treatment with oral corticosteroids within the 30 days before visitvi) No treatment with topical corticosteroids within 15 days before visit	P.anisum-based herbal medicine(Sinupium) 2 drops in each nostril, 2/d (morning, evening), after normal saline irrigation	4 weeks
	N = 22, male/female : 14/8, Age range : 18-66 (mean 37.63)	2) Exclusion criteriai) Nasal and sinus surgery within the last 5 yearsii) Moderate to severe asthma and mild asthma that is exacerbated within 30 days before trialiii) Known hypersensitivity to the medication or excipientsiv) Acute seasonal allergyv) The signs and symptoms of bacterial sinusitis (fever≥38.5)vi) Other diseases, which in the opinion of the investigator disqualifies the patient for trial enrolmentvii) During pregnancy and breastfeedingviii) Any side effect during treatment	Fluticasone nasal spray 2 puffs (total 200㎍) in each nostril, 2/d(morning, evening), after normal saline irrigation
Chen XX17) (2011)	N = 57, male/female : 36/21, Age range : 18-53 (mean 27.43)	1) Inclusion criteriai) Patients had received a diagnosis of PAR- 3 or more symptoms of rhinitis (itching, sneezing, runny nose, and nasal congestion) for at least 30 minutes per day- Physical exam signs : pallor of the nasal mucosa, swollen turbinate- Positive nasal smear of eosinophil, during allergic attack- A positive serum allergens testii) Patients 16 to 65 year of both genders	QTNSA 2-3 puffs (0.3ml per puff) in each nostril, 2/d	2 courses (7days per course)
	N = 46, male/female : 30/16 , Age range : 17-61 (mean 30.78)	2) Exclusion criteriai) Acute seasonal allergy, vasomotor rhinitis, sinusitis, nasal polypii) During pregnancy and breastfeedingiii) Serious histories of cardiovascular, cerebrovascular, hepatic, renal, hematological and psychiatric diseasesiv) Patients refuse treatment methods of this study	Beconase nasal spray 2-3 puffs (50㎍ per puff) in each nostril, 2/d
Wang SL18) (2015)	N = 25, male/female : 5/20, Age range : mean 33.76	1) Inclusion criteriai) Patients had received a diagnosis of ARii) With diagnosis of deficiency of Qi and blood stasis, according to TCMiii) Patients 8 to 60 years of both gendersiv) No other treatment within 1 week of screening	Likemin nasal spray, 2 puffs in each nostril, 2/d	3 weeks of treatment, 4 weeks of follow-up (total 7 weeks)
	N = 27, male/female : 5/22, Age range : mean 38.55	2) Exclusion criteriai) Requiring chronic use of aspirin, glucocorticoid, or corticosteroid; Usage of them within 3 months of screeningii) During pregnancy and breastfeedingiii) Serious histories of cardiovascular, cerebrovascular, hepatic, renal and other diseasesiv) Current history of asthma or other atopic diseasev) Any clinically significant nasal disease of structural abnormalities(including nasal polyps, septal deviation), chronic sinusitisvi) Severe disease like malignant tumorvii) Receiving immunotherapy (desensitization therapy); Usage of antihistamine within 3 days of screeningviii) Participating in other drug clinical trials	Mometasone furoate nasal spray, 2 puffs in each nostril, 1/d
Yu MZ19) (2014)	N = 50, male/female : 61/39, Age range : 18-50	1) Inclusion criteriai) Patients had received a diagnosis of SAR or PAR that occurs at the same time every yearii) 3 symptoms : swollen turbinate, clear rhinorrhea, sneezingiii) At least a 2-year history of ARiv) Positive nasal smear of eosinophil, during allergic attack	Fufanggancaosuan nasal drops, 1-2 drops in each nostril, 3/d	3 weeks
	N = 50, male/female : 61/39, Age range : 18-50	2) Exclusion criteria : Not mentioned	Beclomethasone nasal spray, 1-2puffs in each nostril, 2/d
Ye SZ20) (2011)	N = 212, male/female : 110/102, Age range : 2-73	1) Inclusion criteriai) Patients had received a diagnosis of AR- ≥ 1 year history of AR complained nasal itching, sneezing, nasal obstruction and runny nose- Symptoms of rhinitis for at least 30 minutes per day; at least 6 months per year- Positive skin prick test to a specific allergen- Serum IgE>0.09mg/L	Ultrasonic nebulization of Cangxinye, 10min, 1/d	7days per course → total 3 courses
	N = 188, male/female : 97/91, Age range : 2-73	2) Exclusion criteria : Not mentioned	Ultrasonic nebulization of NS 20ml + Gentamycin sulfate 80,000u + Dexamethasone 2mg nebulization, 10min, 1/d, 7days per course → total 3 courses
Qi XY21) (2014)	N = 38, male/female : 26/12, Age range : mean 31.23	1) Inclusion criteriai) Patients had received a diagnosis of ARii) Patients 18 to 60 years of both genders	Xinyi nasal drops, 3 drops in each nostril, 3/d	3 weeks
	N = 38, male/female : 24/14, Age range : mean 29.28	2) Exclusion criteriai) Usage of other steroids/antihistamine within 1 month of screeningii) During pregnancy and breastfeedingiii) Allergic asthmaiv) Upper respiratory tract infectionvi) Serious histories of cardiovascular, cerebrovascular, hepatic, renal, hematological and other diseases	Azelastine hydrochloride nasal spray, 1 puff in each nostril, 2/d
Wang DH22) (2000)	N = 40, male/female : 26/14, Age range : 14-80 (mean 48.00)	Not mentioned	10% Tuimindibiye 0.1ml nasal drop, 3/d	15 days
	N = 30, male/female : 21/9, Age range : 18-75 (mean 44.00)		1% ephedrine + NS + dexamethasone 0.1ml nasal drop, 3/d
Zhao Y23) (2003)	N = 80, male/female : 56/24, Age range : 15-45 (mean 31.80)	1) Inclusion criteriai) Patients who meet allergic rhinitis diagnosis criteria	Biyanqing nasal drop, 4-6/d, 1/w	3 weeks
	N = 42, male/female : 16/26, Age range : 14-45 (mean 31.90)	2) Exclusion criteriai) Undiagnosed patientsii) Patients who suffer from too many diseases or who have certain other diseases.iii) Patients under 15 or over 45 yearsiv) During pregnancy and breastfeedingv) Patients who are allergic to this medicationvi) Those who may not be able to determine the effectiveness of treatment after taking medicine or may have incomplete clinical data that may affect treatment efficacy or safety judgements.	Ephedrine Hydrochloride and Nitrofurazone nasal drop, 4-6/d, 1/w
Huang ZY24) (2006)	N = 71, male/female : 36/35, Age range : mean 49.32	Not mentioned	Biminshuidibiye 10ml, 2 drops in each nostril, 3/d	3 weeks
	N = 65, male/female : 32/33, Age range : mean 48.25		1% Furosemide 10ml+Dexamethasone 5mg, 2 drops in each nostril, 3/d
Huang RQ25) (2007)	N = 85, male/femnale : 75/60, Age range : 10-60 (mean 30.00)	Not mentioned	Fumigation 30ml, 3-5/d, 15mins• Wind-cold pattern• Wind-heat pattern• Lung-heat pattern	5 days
	N = 50, male/female : 75/60, Age range : 10-60 (mean 30.00)		Ephedrine 30mg + Dexamethasone 5mg + DW 30ml, ultrasonic nebulization, 2/d, 15mins
Zhao Y26) (2008)	N = 150, male/female : 90/60, Age range : 14-48 (mean 31.80)	1) Inclusion criteria : Not mentioned	Biyanqing nasal drop, 4-6/d	3 weeks
	N = 105, male/female : 65/45, Age range : 13-49 (mean 31.90)	2) Exclusion criteriai) Patients who have not received an accurate diagnosis or have other excessive diseaseii) Patients under 13 or over 50 yearsiii) During pregnancy and breastfeedingiv) Patients who are allergic to this medicationv) Patients who affect the treatment effect or safety judgement, such as not meeting the criteria, not taking the drug according to the regulations, unable to determine the therapeutic effect, or having incomplete clinical data.	Furosemide nasal drop, 4-6/d
Wu XL27) (2016)	N = 21	1) Inclusion criteriai) Patients who have been diagnosed with PAR in Western medicine and TCM- 3 or more symptoms of rhinitis (itching, sneezing, runny nose, and nasal congestion) for 30 min-1 hr or more per day, 4 times or more per week.- Physical exam signs : swollen turbinate; pale, gray or light blue or bloody red nasal mucosa; a large amount of watery secretions in the nasal cavity and nasal passages- A positive allergic IgE test- Positive nasal smear for eosinophils during allergic attack- Patients who meet the 'Qi deficiency and blood stasis' patternii) Patients with presence of PAR symptoms for at least 1 yearsiii) Patients 8 to 60 years of both gendersiv) No treatment within 4 weeks before visit	Keminmiaodanbipenwuji nasal drop, 2 drops in each nostril, 2/d (morning, night)	21 days
	N = 22	2) Exclusion criteriai) Patients who need to take aspirin, glucocorticoids, or long-lasting corticosteroids for a long time or in the last three monthsii) During pregnancy and breastfeedingiii) Patients with severe organic disorders in the heart, brain, kidneys, liver, etc.iv) Patients with bronchial asthma or specific dermatitisv) Patients with nasal diseases such as significant septal curvature, nasal polyps or chronic sinusitisvi) Patients with severe illness such as malignant tumorvii) Patients with skin disease or mental illnessviii) Patients who are receiving certain immunotherapy or taking antihistamines within 3 daysix) Patients participating in other drug clinical trials	Mometasone Furoate nasal spray, 2 puffs in each nostril, 2/d (morning, night)
Weng KH28) (2016)	N = 20, male/female : 11/9, Age range : 3-13 (mean 8.40)	1) Inclusion criteriai) Patients had received a diagnosis of PARii) Patients 2 to 14 yeariii) Patients who are suffering allergic attack at first visitiv) Without any treatment (like oral glucosteroids)	XingBiWenMinNingJiaoJi nasal spray 1 puffs in each nostril, 2/d	4 weeks
	N = 20, male/female : 15/5 , Age range : 3-12 (mean 7.00)	2) Exclusion criteriai) Serious histories of cardiovascular, cerebrovascular, hepatic, renal, hematological and psychiatric diseasesii) During the asthmatic attackiii) Usage of other oral/nasal antihistamine within 1 week of screening or nasal spray/drop steroids within 1 week of screeningiv) Usage of systemic steroids within 4 weeks of screeningv) Ongoing use of macrolides antibiotics and(or) antifungal drugs	Budesonide nasal spray, 2/d (total 256㎍ per day)
Li XW29) (2016)	N = 20, male/female : 14/6, Age range : mean 7.00	1) Inclusion criteriai) Patients had received a diagnosis of PARii) Patients 3 to 14 yeariii) Patients who are suffering allergic attack at first visit	Xingbiwenmin nasal spray, 1 puffs in each nostril, 2/d(morning, evening)	4 weeks
	N = 20, male/female : 15/5, Age range : mean 7.60	2) Exclusion criteriai) Usage of other treatment that could affect the deposition of the study medicationsii) Serious histories of cardiovascular, cerebrovascular, hepatic, renal, hematological and psychiatric diseasesiii) During the asthma attackiv) Any clinically significant nasal disease of structural abnormalities(including nasal polyps, septal deviation, adenoidal hypertrophy), chronic rhinitis(including acute/chronic sinusitis, atrophic rhinitis)v) Known hypersensitivity to the medication or excipients	Budesonide nasal spray, 1 puff in each nostril, 2/d(morning, evening)
Zeng MY30) (2012)	N = 100, male/female : 53/47, Age range : 2-14	1) Inclusion criteriai) Patients had received a diagnosis of AR- ≥ 1 year history of AR complained nasal itching, sneezing, nasal obstruction and runny nose- Symptoms of rhinitis for at least 30 minutes per day; at least 6 months per year- Positive skin prick test to a specific allergen- Personal or first-degree relative history of allergic diseases- Serum IgE>0.09mg/L	Ultrasonic nebulization of LXFMB, 10mins, 1/d, 7 days per course → total 3 courses	7 days per course → total 3 courses
	N = 100, male/female : 52/48 , Age range : 2-14	2) Exclusion criteria : Not mentioned	Ultrasonic nebulization of Gentamicin 80,000U + Dexamethasone(DXM) 2mg, 10mins, 1/d, 7 days per course → total 3 courses
Luo HY31) (2007)	N = 15, male/female : 9/6, Age range : mean 7.85	1) Inclusion criteriai) Patients had received a diagnosis of ARii) Patients 3 to 14 years of both gendersiii) Patients who are suffering allergic attack at first visit	Xingbiningjiaoji nasal spray, 1 puff in each nostril, 2/d	4 weeks
	N = 15, male/female : 9/6, Age range : mean 7.32	2) Exclusion criteriai) Usage of other treatment that could affect the deposition of the study medicationsii) Serious histories of cardiovascular, cerebrovascular, hepatic, renal, hematological, psychiatric and other diseases	Budesonide nasal spray, 1 puff in each nostril, 2/d (total 256㎍)
Liu CZ32) (2004)	N = 140, male/female : 63/77, Age range : 5-16 (mean 12.00)	Not mentioned	Inhalation total 12ml with atomizer, 15min, 2/d• Wind-cold pattern : No.7 6ml+No.1 6ml• Gallbladder heat pattern : No.7 6ml+No.2 6ml• Wind-heat pattern : No.7 6ml+No.6 6ml	1 week
	N = 60, male/female : 26/34, Age range : 6-16 (mean 12.00)		Dexamethasone 5mg, Chymotrypsin 5mg, Gentamicin 40,000u, and NS 5ml inhalation, 15min, 2/d
Wang TT33) (2013)	N = 25, male/female : 15/10, Age range : mean 4.4	1) Inclusion criteriai) Patients who meet the criteria for AR diagnosis in Western medicine and TCMii) Patients 2 to 6 yearsiii) Patients who are suffering allergic attack at first visit	Zhongyaodibiye nasal drop, 1-2 drops in each nostril, 2/d (morning, night)	4 weeks
	N = 25, male/female : 11/14, Age range : mean 5.2	2) Exclusion criteriai) Those who do not meet the diagnostic criteria and inclusion criteriaii) Those who received treatment that could affect the effectiveness indicator of the study	Sodium cromoglucate nasal drop, 1-2 drops in each nostril, 2/d (morning, night)
Zheng J34) (2010)	N = 50, male/female : 31/19, Age range : mean 7.68	1) Inclusion criteriai) Patients who meet the criteria for AR diagnosis in Western medicine and TCMii) Patients 3 to 14 yearsiii) Patients who are suffering allergic attack at first visit	Zhongyaoxingbiningjiaodiji nasal spray, 1 puff in each nostril, 2/d	4 weeks
	N = 50, male/female : 29/21, Age range : mean 7.33	2) Exclusion criteriai) Those who do not meet the diagnostic criteria and inclusion criteriaii) Those who received treatment that could affect the effectiveness indicator of the studyiii) Poor compliance with diagnosis, treatment and follow-up	Budesonide nasal spray, 1 puff in each nostril, 2/d(total 256 μg per day)